ElevateBio removes barriers to accelerate the development of visionary therapies

Viralym-M (ALVR105)
Multi-VSTs targeting BK Virus (BKV), Cytomegalovirus (CMV), Adenovirus (AdV), Epstein-Barr (EBV), and Human Herpesvirus-6 (HHV-6)
Target Indication
Preclinical
POC Trial (Phase 1b/2)
Pivotal Trial (Phase 3)
Treatment of Virus-Associated Hemorrhagic-Cystitis
Treatment of CMV
Treatment of ADV
Prevention of BKV, CMV, AdV, EBV, HHV-6 and JCV
BKV Pre-emptive Treatment in KT
Treatment of CMV
ALVR106
Multi-VSTs targeting Respiratory syncytial virus (RSV), Influenza, Parainfluenza Virus (PIV), and Human Metapneumovirus (hMPV)
Target Indication
Preclinical
POC Trial (Phase 1b/2)
Pivotal Trial (Phase 3)
Treatment of RSV, Influenza, PIV, & hMPV
IND Cleared in Q4 2020
Treatment of RSV, Influenza, PIV, & hMPV
ALVR109
Single-VST targeting SARS-CoV-2
Target Indication
Preclinical
POC Trial (Phase 1b/2)
Pivotal Trial (Phase 3)
Treatment of COVID-19
ALVR107
Single-VST targeting Hepatitis B (HBV)
Target Indication
Preclinical
POC Trial (Phase 1b/2)
Pivotal Trial (Phase 3)
Treatment of HBV
ALVR108
Single-VST targeting Human Herpesvirus-8 (HHV-8)
Target Indication
Preclinical
POC Trial (Phase 1b/2)
Pivotal Trial (Phase 3)
Treatment of HHV-8
HA-1 TCR
T cell receptor (TCR) T cell therapy targeting HA-1 expressing tumors designed to manage post-hematopoietic stem cell transplant leukemic relapse
Indication
Preclinical
Phase 1
Phase 2
Phase 3
HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Committed to identifying and nurturing
innovation in cell and gene therapy

Our partners are enabled by our technologies, state-of-the-art process development and manufacturing facility, and collaboration with our entrepreneurial and flexible culture, allowing them to focus on science, research, and development.

We’re the partner of choice for the world’s most innovative biopharma companies and academic institutions.

Building an alliance with Massachusetts General Hospital

“MGH researchers and clinicians continue to make unprecedented progress for patients as they develop novel cell and gene therapies,” said Peter L. Slavin, MD, president of the MGH.

“This collaboration with ElevateBio will enable us to amplify our efforts in the development and manufacture of cell and gene therapies.”

learn more

Translating research into life-changing treatments with Boston Children’s Hospital

"At Boston Children’s Hospital, we are proud of the foundation we’ve established as a leading innovator in cell and gene therapy, so collaborating with ElevateBio— a company so well positioned to change the face of cell and gene therapy forever— is a natural fit into our overall vision,” said David Williams, MD, the hospital’s chief of hematology/oncology. “Using ElevateBio’s world-class enabling technologies, this alliance will help catalyze the science being conducted in the labs across Boston Children’s."

LEARN MORE

Academic researchers provide the vision, we provide the technologies and capabilities.

ElevateBio’s proven expertise in the discovery and development of new cell and gene therapies is driven by the vision of academic partners in the advancement of life-changing treatments. We offer a new approach for alliance building, and the development of new companies with the world’s leading scientific leaders, to advance their highly innovative programs quickly and efficiently.

Core to ElevateBio’s vision is BaseCamp, a centralized state-of-the-art innovation and manufacturing center, providing fully integrated capabilities, including basic and translational research, process development, clinical development, cGMP manufacturing, and regulatory affairs across multiple cell and gene therapy and regenerative medicine technology platforms. ElevateBio portfolio companies, as well as select strategic partners, are supported by ElevateBio. BaseCamp Academic researchers provide the vision, we provide the technology.

explore basecamp

Connect to learn more about partnering with ElevateBio

Work with a team that delivers decades of experience

Meet the scientists and operators that bring decades of shared knowledge to the development of life transforming cell and gene therapies. Their knowhow moves potential product candidates from concept to commercialization.

meet the team